Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3387MR)

This product GTTS-WQ3387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5037MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ13152MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ12316MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ12865MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ12864MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ4622MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ9129MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ11598MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW